NAV

Efrotomycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Efrotomycin
DrugBank Accession Number
DB11401
Background

Not Available

Type
Small Molecule
Groups
Vet approved
Structure
Similar Structures
Weight
Average: 1145.347
Monoisotopic: 1144.593043242
Chemical Formula
C59H88N2O20
Synonyms
  • Efrotomycin
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcenocoumarolThe risk or severity of bleeding can be increased when Efrotomycin is combined with Acenocoumarol.
AmbroxolThe risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Articaine.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Efrotomycin.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Benzocaine.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
O-glycosyl compounds
Alternative Parents
C-glycosyl compounds / Disaccharides / Tetrahydropyridines / Oxanes / Vinylogous amides / Vinylogous acids / Tertiary carboxylic acid amides / Oxolanes / Secondary alcohols / Cyclic ketones
show 14 more
Substituents
Acetal / Alcohol / Aldehyde / Aliphatic heteromonocyclic compound / Azacycle / C-glycosyl compound / Carbonyl group / Carboxamide group / Carboximidic acid / Carboximidic acid derivative
show 27 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
5BPJ82Q45X
CAS number
Not Available
InChI Key
ZLECMEJICSWJLT-LIWMBINXSA-N
InChI
InChI=1S/C59H88N2O20/c1-15-17-19-27-39-58(8,9)53(80-56-45(67)50(74-13)49(35(7)76-56)79-57-51(75-14)44(66)48(73-12)34(6)77-57)52(68)59(71,81-39)36(16-2)54(69)60-29-23-22-25-32(4)46(72-11)33(5)47-43(65)42(64)38(78-47)26-21-18-20-24-31(3)41(63)40-37(62)28-30-61(10)55(40)70/h15,17-28,30,33-36,38-39,42-53,56-57,63-68,71H,16,29H2,1-14H3,(H,60,69)/b17-15+,20-18+,23-22+,26-21+,27-19+,31-24+,32-25+,41-40+
IUPAC Name
2-[2,3-dihydroxy-4-({3-hydroxy-5-[(4-hydroxy-3,5-dimethoxy-6-methyloxan-2-yl)oxy]-4-methoxy-6-methyloxan-2-yl}oxy)-5,5-dimethyl-6-[(1E,3E)-penta-1,3-dien-1-yl]oxan-2-yl]-N-[(2E,4E)-7-{3,4-dihydroxy-5-[(1E,3E,5E)-7-hydroxy-6-methyl-7-[(3Z)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyridin-3-ylidene]hepta-1,3,5-trien-1-yl]oxolan-2-yl}-6-methoxy-5-methylocta-2,4-dien-1-yl]butanimidic acid
SMILES
[H]\C(C)=C(\[H])/C(/[H])=C(\[H])C1OC(O)(C(CC)C(O)=NC\C([H])=C(/[H])\C(\[H])=C(/C)C(OC)C(C)C2OC(\C([H])=C(/[H])\C(\[H])=C(/[H])C([H])=C(C)C(\O)=C3\C(=O)C=CN(C)C3=O)C(O)C2O)C(O)C(OC2OC(C)C(OC3OC(C)C(OC)C(O)C3OC)C(OC)C2O)C1(C)C

References

General References
  1. Frost BM, Valiant ME, Weissberger B, Dulaney EL: Antibacterial activity of efrotomycin. J Antibiot (Tokyo). 1976 Oct;29(10):1083-91. [Article]
  2. Frost BM, Valiant ME, Dulaney EL: Synergism between efrotomycin and bottromycin. J Antibiot (Tokyo). 1979 Oct;32(10):1046-9. [Article]
  3. Wax R, Maises W, Weston R, Birnbaum J: Efrotomycin, a new antibiotic from Streptomyces lactamdurans. J Antibiot (Tokyo). 1976 Jun;29(6):670-3. [Article]
  4. Nielsen JB, Kaplan L: A resting cell system for efrotomycin biosynthesis. J Antibiot (Tokyo). 1989 Jun;42(6):944-51. [Article]
  5. Stong JD: Determination of efrotomycin in feeds by high-performance liquid chromatography. Analyst. 1986 Jul;111(7):853-5. [Article]
  6. Chartrain M, Hunt G, Horn L, Kirpekar A, Mathre D, Powell A, Wassel L, Nielsen J, Buckland B, Greasham R: Biochemical and physiological characterization of the efrotomycin fermentation. J Ind Microbiol. 1991 Jun;7(4):293-9. [Article]
  7. Cover WH, Kirpekar AC, George H, Stieber RW: Calcium inhibition of efrotomycin production by Nocardia lactamdurans. J Ind Microbiol. 1991 Jan;7(1):41-4. [Article]
  8. Darland G, Arison B, Kaplan L: The biosynthetic origin of the pyridone ring of efrotomycin. J Ind Microbiol. 1991 Nov;8(4):265-71. [Article]
  9. Stutz MW, Johnson SL, Judith FR, Miller BM: In vitro and in vivo evaluations of the antibiotic efrotomycin. Poult Sci. 1983 Aug;62(8):1612-8. [Article]
  10. Dewey RS, Arison BH, Hannah J, Shih DH, Albers-Schonberg G: The structure of efrotomycin. J Antibiot (Tokyo). 1985 Dec;38(12):1691-8. [Article]
Not Available

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0166 mg/mLALOGPS
logP5.03ALOGPS
logP4.23Chemaxon
logS-4.8ALOGPS
pKa (Strongest Acidic)4.97Chemaxon
pKa (Strongest Basic)2.96Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count21Chemaxon
Hydrogen Donor Count8Chemaxon
Polar Surface Area303.88 Å2Chemaxon
Rotatable Bond Count23Chemaxon
Refractivity304.22 m3·mol-1Chemaxon
Polarizability124.59 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00mk-0800000900-ae43c801c69d95c375ec
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-0906000000-f955283c14cd848060c9
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0595-2972000202-7918753620cfcb4598c7
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-2903012100-f18c33e574fe7512bae1
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9813061002-0264900d3eaee816bd4d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fdk-3930230100-93c45f0f664929b6edbc
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-348.44336
predicted
DeepCCS 1.0 (2019)
[M+H]+350.16708
predicted
DeepCCS 1.0 (2019)
[M+Na]+356.36765
predicted
DeepCCS 1.0 (2019)

Drug created at February 25, 2016 18:25 / Updated at February 21, 2021 18:53